HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
15.04
-0.21 (-1.38%)
At close: Mar 31, 2025, 4:00 PM
15.08
+0.04 (0.30%)
After-hours: Mar 31, 2025, 6:47 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
$347,985
Profits / Employee
$20,833
Market Cap
2.56B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HCM News
- 10 days ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 11 days ago - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewsWire
- 11 days ago - HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewsWire
- 12 days ago - HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength - Benzinga
- 12 days ago - HUTCHMED Reports 2024 Full Year Results and Provides Business Updates - GlobeNewsWire
- 12 days ago - HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China - GlobeNewsWire
- 25 days ago - HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China - GlobeNewsWire